tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Percheron Therapeutics Unveils Promising Preclinical Data for HMBD-002 in Triple-Negative Breast Cancer

Story Highlights
Percheron Therapeutics Unveils Promising Preclinical Data for HMBD-002 in Triple-Negative Breast Cancer

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from Percheron Therapeutics ( (AU:PER) ) is now available.

Percheron Therapeutics has announced new preclinical data demonstrating the activity of its investigational cancer drug, HMBD-002, in treating triple-negative breast cancer (TNBC). This research, conducted by the University of Texas Southwestern Medical Center, highlights the drug’s potential to inhibit tumor growth in VISTA-expressing TNBC, a particularly aggressive and treatment-resistant form of cancer. The findings suggest that HMBD-002 could offer a new avenue for addressing the unmet clinical needs of TNBC patients, potentially differentiating itself from existing immunotherapies by also modulating growth signals. The company plans to further evaluate HMBD-002’s development and expects to share phase I data by the end of 2025.

The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.

More about Percheron Therapeutics

Percheron Therapeutics Limited is an international biotechnology company focused on developing novel therapies for oncology and rare diseases.

Average Trading Volume: 2,296,306

Technical Sentiment Signal: Sell

Current Market Cap: A$9.79M

See more data about PER stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1